XML 24 R7.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND SHAREHOLDERS’ EQUITY (DEFICIT) - USD ($)
$ in Millions
Total
Common Stock
Common Stock
Restricted Shares
Common Stock
RSUs
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Series A Convertible Preferred Stock
Series B Convertible Preferred Stock
Series C Convertible Preferred Stock
Series D Convertible Preferred Stock
Series D Convertible Preferred Stock
Additional Paid-in Capital
Series E Convertible Preferred Stock
Series E Convertible Preferred Stock
Additional Paid-in Capital
Temporary equity, shares outstanding, beginning balance (in shares) at Dec. 31, 2019               40,089,513 23,840,816 29,070,700 63,470,884   157,952,523  
Temporary equity, beginning balance at Dec. 31, 2019               $ 10 $ 20 $ 81 $ 258   $ 1,013  
Temporary Equity [Abstract]                            
Issuance of preferred stock (Series D, Series E) (in shares)                     485,262   364,070  
Issuance of preferred stock (Series D, Series E)                     $ 2   $ 2  
Temporary equity, shares outstanding, ending balance (in shares) at Dec. 31, 2020               0 0 0 0   0  
Temporary equity, ending balance at Dec. 31, 2020               $ 0 $ 0 $ 0 $ 0   $ 0  
Shares outstanding, beginning balance (in shares) at Dec. 31, 2019   83,748,443                        
Shareholders' equity (deficit) beginning balance at Dec. 31, 2019 $ (733) $ 0     $ 57 $ (790) $ 0              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Issuance of stock 1       1           $ 3 $ 3 $ 1 $ 1
Issuance of issuer stock rights in extinguishment of the 2019 Convertible Notes 213       213                  
Issuance of common stock in exchange for issuer stock rights (in shares)   21,460,401                        
Issuance of stock (in shares)   1,389,585                        
Vesting of restricted stock (in shares)   1,461,844                        
Vesting of restricted shares 0       0                  
Exercise of stock options (in shares)   5,638,019                        
Exercise of stock options 8       8                  
Conversion of common and preferred stock (in shares)   315,273,768           (40,089,513) (23,840,816) (29,070,700) (63,956,146)   (158,316,593)  
Conversion of common and preferred stock 1,386       1,386     $ (10) $ (20) $ (81) $ (260)   $ (1,015)  
Issuance of common stock in connection with acquisition (in shares)   111,742,632                        
Issuance of common stock in stock in connection with acquisition 889       889                  
Stock-based compensation 38       38                  
Net loss (253)         (253)                
Shares outstanding, ending balance (in shares) at Dec. 31, 2020   540,714,692                        
Shareholders' equity (deficit) ending balance at Dec. 31, 2020 1,553 $ 0     2,596 (1,043) 0              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Issuance of stock 857       857                  
Issuance of stock (in shares)   32,817,421                        
Vesting of restricted stock (in shares)     1,370,447 24,004,565                    
Exercise of stock options (in shares)   8,919,289                        
Exercise of stock options $ 15       15                  
Conversion of common and preferred stock (in shares) 195,000,000 8,200,151                        
Conversion of common and preferred stock $ 58       58                  
Stock-based compensation 548       548                  
Purchases of Capped Calls related to the 2026 Notes (119)       (119)                  
Other comprehensive income (2)           (2)              
Net loss $ (662)         (662)                
Shares outstanding, ending balance (in shares) at Dec. 31, 2021 616,026,565 616,026,565                        
Shareholders' equity (deficit) ending balance at Dec. 31, 2021 $ 2,248 $ 0     3,955 (1,705) (2)              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Vesting of restricted stock (in shares)     628,193 17,279,891                    
Exercise of stock options (in shares) 2,959,000 2,958,586                        
Exercise of stock options $ 4       4                  
Employee stock purchase plan (in shares)   493,790                        
Employee stock purchase plan 2       2                  
Stock-based compensation 187       187                  
Other comprehensive income (2)           (2)              
Net loss $ (1,353)         (1,353)                
Shares outstanding, ending balance (in shares) at Dec. 31, 2022 637,387,025 637,387,025                        
Shareholders' equity (deficit) ending balance at Dec. 31, 2022 $ 1,086 $ 0     $ 4,148 $ (3,058) $ (4)